Early Mineralocorticoid Receptor Antagonist Therapy for Low-Renin Essential Hypertension
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 128 participants.
Also called NCT07932145
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 128 participants
- Registry
-
NCT07932145
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07932145. Randomized; single masking; primary purpose treatment. Start 2026-12-01 (anticipated); primary completion 2027-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Early Mineralocorticoid Receptor Antagonist Therapy for Low-Renin Essential Hypertension
- Acronym
- EMERALD
- Condition
- Hypertension (HTN)
- Condition
- Low-Renin Essential Hypertension
- Intervention (Drug)
- Eplerenone
- Intervention (Drug)
- Telmisartan
- Lead sponsor
- China National Center for Cardiovascular Diseases
Record details
- Record id
cardio:ct-nct07932145- Content hash
9ac62d7cba2b05e4860400b2ac2f10dcd8ca5421572259188cfb1790f5da8afb